Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 22, 2015 08:20 ET | Source: Genmab A/S

Genmab meddeler, at der er indsendt en supplerende registreringsansøgning til FDA for ofatumumab som vedligeholdelsesbehandling af recidiverende CLL

Selskabsmeddelelse Supplerende registreringsansøgning indsendt af Novartis til FDA i USA for ofatumumab som vedligeholdelsesbehandling af recidiverende CLL Ansøgningen er baseret på data...
July 22, 2015 08:20 ET | Source: Genmab A/S

Genmab Announces Submission of Supplemental Biologics License Application to FDA for Ofatumumab as Maintenance Therapy for Relapsed CLL

Company Announcement sBLA submitted to US FDA for ofatumumab as maintenance therapy in relapsed CLL by Novartis Submission based on data from interim results of Phase III PROLONG...
July 10, 2015 11:50 ET | Source: Genmab A/S

Storaktionærmeddelelse

Selskabsmeddelelse Storaktionærmeddelelse for Genmab A/S København, Danmark, 10. juli 2015 – Genmab A/S (OMX: GEN) skal under henvisning til Værdipapirhandelslovens § 29 meddele, at ATP har...
July 10, 2015 11:50 ET | Source: Genmab A/S

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; July 10, 2015 – Genmab A/S (OMX: GEN) announces under reference to Section 29 of the Danish Securities...
July 09, 2015 13:47 ET | Source: Genmab A/S

Genmab offentliggør færdiggørelsen af en løbende registreringsansøgning (Rolling Biologics License Application) for daratumumab i myelomatose og opnåelsen af en milepælsbetaling på USD 15 mio.

Selskabsmeddelelse Janssen Biotech, Inc. færdiggør indleveringen af den løbende BLA-ansøgning til FDA i USA for daratumumab i myelomatose Færdiggørelsen af indleveringen udløser en...
July 09, 2015 13:47 ET | Source: Genmab A/S

Genmab Announces Completion of Rolling Submission of Biologics License Application for Daratumumab in Multiple Myeloma and Achievement of a USD 15 Million Milestone

Company Announcement Submission of rolling BLA to US FDA for daratumumab in multiple myeloma completed by Janssen Biotech, Inc. Completion of submission triggers USD 15 million milestone...
July 07, 2015 07:29 ET | Source: Genmab A/S

Genmab Announces European Regulatory Submission for Ofatumumab as Maintenance Therapy for Relapsed CLL

Company Announcement Application to broaden label for ofatumumab as maintenance therapy in relapsed CLL submitted to EMA by Novartis Submission based on data from interim results of Phase...
July 07, 2015 07:29 ET | Source: Genmab A/S

Genmab meddeler, at der er indsendt registreringsansøgning for ofatumumab som vedligeholdelsesbehandling af recidiverende CLL i Europa

Selskabsmeddelelse Ansøgning om at udvide indikationsområdet for ofatumumab som vedligeholdelsesbehandling af recidiverende CLL indsendt af Novartis til EMA Ansøgningen er baseret på data...
June 23, 2015 11:22 ET | Source: Genmab A/S

Selskabsvedtægter for Genmab A/S

Selskabsvedtægter for Genmab A/S dateret den 11. juni 2015 er blevet offentliggjort. Selskabsvedtægterne er tilgængelige på Genmabs hjemmeside:...
June 23, 2015 11:22 ET | Source: Genmab A/S

Articles of Association for Genmab A/S

Genmab A/S has published its Articles of Association dated June 11, 2015. The Articles of Association can be found on Genmab’s website: http://ir.genmab.com/releases.cfm Contact: Rachel Curtis...